Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 23, 2023
March 28, 2024
529cc738-130c-4b4d-afb4-d2ea5f0fe894
Related Documents
Questions and Answers on Quality Related Controlled Correspondence Guidance for Industry: Guidance for Industry
Guidance DocumentSeptember 20, 2021Center for Drug Evaluation and Research
Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry: Guidance for Industry
Guidance DocumentJune 8, 2023Center for Drug Evaluation and Research
ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions
Guidance DocumentJune 16, 2025Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox